Senior Leadership

//Senior Leadership
Senior Leadership 2018-08-03T13:40:52+00:00

The Oncobiologics Team

We have assembled a team of industry veterans, with decades of cumulative experience in biologics development and commercialization at such organizations as Bristol-Myers Squibb Company, Genentech, Inc., Hoffman-La Roche, Amgen, Shire, Genzyme, NPS Pharmaceuticals, Inc. and Savient Pharmaceuticals, Inc. Our leadership team has also been instrumental in obtaining global regulatory approval for multiple complex biologics at leading multinational biopharmaceutical companies. Our scientific team has specific experience in process development for complex biologics, protein manufacturing and analytical research and development, which are essential components for the development and manufacturing of complex biosimilars.

Oncobiologics combines the world-class know-how of leading discovery and development scientists with the agile, innovative culture of a start-up. We have also developed an expert advisory team and partnerships with leading institutions to complement our capabilities.


Lawrence A. Kenyon

President, Chief Executive Officer & Chief Financial Officer

Mr. Kenyon has served as our President and CEO and as a member of our board of directors since August 2018.  He has also served as our Chief Financial Officer and Secretary since September 2015. Prior to that, from February 2014 to September 2015, Mr. Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, and also as Chief Operating Officer from July 2014 to September 2015. From December 2011 to March 2013, Mr. Kenyon served as the Interim President & Chief Executive Officer, Chief Financial Officer and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics. Prior to that, from December 2008 to July 2010, Mr. Kenyon was the Executive Vice President, Finance and, commencing in March 2009, the Chief Financial Officer of, Par Pharmaceutical Companies, Inc., a publicly held generic and branded specialty pharmaceutical company, or Par. Prior to joining Par, Mr. Kenyon was the Chief Financial Officer and Secretary of Alfacell Corporation, or Alfacell, from January 2007 through February 2009 and also served at various times during this period as Alfacell’s Executive Vice President, Chief Operating Officer and President, and was a member of Alfacell’s board of directors from November 2007 to April 2009. Prior to joining Alfacell, Mr. Kenyon served as the Executive Vice President, Chief Financial Officer and Corporate Secretary at NeoPharm, Inc., a publicly traded biopharmaceutical company, from 2000 to 2006.

Mr. Kenyon received a B.A. in Accounting from the University of Wisconsin-Whitewater and is a Certified Public Accountant in Illinois.

Kenneth M. Bahrt, M.D., F.A.C.R.

Chief Medical Officer

Dr. Bahrt has served as our Chief Medical Officer since June 2015. Prior to joining us, from February 2014 to May 2015, Dr. Bahrt served as the Vice President of U.S. Medical Affairs at NPS Pharmaceuticals, Inc., a biopharmaceutical company. From August 2011 to January 2014, Dr. Bahrt served as Senior Vice President and Chief Medical Officer at Savient Pharmaceuticals, Inc., a biopharmaceutical company. Prior to that, from September 2009 to August 2011, Dr. Bahrt served as the Therapeutic Head of Immunology Medical Affairs at Genentech, Inc. From July 2007 to September 2009, Dr. Bahrt served as the Global Medical Director for Immunology at Hoffman-La Roche, a Swiss healthcare company. Prior to this, Dr. Bahrt held positions of increasing responsibility at Bristol Myers Squibb, Pfizer, and Daiichi. Prior to joining the pharmaceutical industry Dr Bahrt was in clinical practice.

Dr. Bahrt is a board-certified Internist and Rheumatologist and a Fellow of the American College of Rheumatology. Dr. Bahrt received an M.D. from Hahnemann University and a Bachelor’s degree in Biology from Muhlenberg College.

Stephen J. McAndrew, Ph.D.

Senior Vice President
Business Strategy & Development

Dr. McAndrew served initially as our Vice President of Business Development from February 2012 through March 2014, and as our Senior Vice President, Business Strategy & Development since March 2014. Prior to joining us, from March 2011 to February 2012, Dr. McAndrew served as the President of SJM BioPharma Consulting, a biopharmaceutical consulting company. From December 2009 to March 2011, Dr. McAndrew served as Vice President of Scientific Commercial Development at Taconic Biosciences, Inc., a contract research and biotechnology company, and from August 2007 to December 2009, Dr. McAndrew served as Vice President of Business Development at Caliper Life Sciences, Inc., a biotechnology company. Prior to that, from January 2004 to August 2007, Dr. McAndrew served as Vice President of Business Development at Xenogen Biosciences Corporation, a provider of in vivo drug discovery services. From January 2001 to December 2003, Dr. McAndrew served as Vice President of Pharmaceutical Business Development at Lexicon Pharmaceuticals, Inc., a biopharmaceutical drug development company. Prior to that, from March 1993 to December 2001, Dr. McAndrew served in various positions of increasing responsibility at Bristol-Myers Squibb Company, including as Director of Biotechnology Licensing.

Dr. McAndrew received a Ph.D. in Cellular and Molecular Biology from Ohio University, an M.S. in Molecular Genetics from the State University of New York at Albany and a B.S. from the State University of New York at Oswego.

Chuck Hart

Vice President

Mr. Hart has served as our Vice President of Manufacturing since January 2018. Prior to joining us, from November 2016 until January 2018, Mr. Hart served as Head of Clinical Manufacturing, and prior to that from July 2014 until November 2016 he served as Director of Manufacturing at Prolong Pharmaceuticals, a Biopharmaceutical Development company. From February 2013 until July 2014, Mr. Hart served as Director of Upstream Operations at Genzyme Inc, a Biopharmaceutical company. From October 2009 to February 2013, Mr. Hart served as Director of Upstream Operations, and prior to that from March 2009 until October 2009 he served as Commercial Manufacturing Associate Director at Shire HGT, a Biopharmaceutical company. From March 2006 until March 2009, Mr. Hart served as Associate Director of Downstream Manufacturing at ImClone Inc, a Biopharmaceutical company. Prior to this Mr. Hart held positions of increasing responsibilities at GlaxoSmithKline, Pfizer, Immunex, and Amgen. Mr. Hart brings 27 Years of Biopharmaceutical Manufacturing experience to this role.

Mr. Hart is a graduate of the United States Naval Nuclear Power School, with focus on Nuclear Math and Nuclear Physics.

Myrna Thomas

Myrna Thomas

Vice President
QA/QC, Regulatory Affairs

Ms. Thomas joined Oncobiologics as the Vice President of Quality Assurance, Quality Control and Regulatory Affairs in April 2018. Previously, she was Vice President, QA/QC, RA for Accupac, a contract manufacturer for pharmaceuticals, animal health, medical devices and cosmetics.  Prior to that, she was Senior Director at Merck, with responsibility for worldwide clinical data management for all pharmaceuticals and biologics.  Before Merck, she held the position of Vice President, QA/QC, Manufacturing and Process Development for Fibrocell (formerly Isolagen) and Vice President QA/QC, RA for WuXi/AppTec (formerly AppTec), a contract manufacturer of monoclonal antibodies and therapeutic proteins.  Her experience includes Quality Assurance, Regulatory Affairs, Analytical Chemistry, Microbiology, R&D with specific expertise in Clinical Manufacturing, Commercial Manufacturing and Contract Manufacturing.

Ms. Thomas earned an AAS in Mortuary Science at SUNY Canton, a BS in Biochemistry/Biophysics at SUNY Plattsburgh and an MS in Analytical Chemistry at Illinois Institute of Technology.